Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Shares Issued (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Shares Issued for 16 consecutive years, with -$261000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Shares Issued fell 141.3% to -$261000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $893000.0, a 1340.32% increase, with the full-year FY2024 number at $708000.0, up 2978.26% from a year prior.
  • Shares Issued was -$261000.0 for Q4 2025 at Anika Therapeutics, down from $261000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $650000.0 in Q4 2022 to a low of -$1.0 million in Q4 2021.
  • A 5-year average of $107384.6 and a median of $30000.0 in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: plummeted 1391.18% in 2021, then surged 4614.29% in 2024.
  • Anika Therapeutics' Shares Issued stood at -$1.0 million in 2021, then skyrocketed by 164.1% to $650000.0 in 2022, then tumbled by 102.15% to -$14000.0 in 2023, then soared by 4614.29% to $632000.0 in 2024, then tumbled by 141.3% to -$261000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Shares Issued are -$261000.0 (Q4 2025), $261000.0 (Q2 2025), and $632000.0 (Q4 2024).